Subscribe To
CANSF / Willow Biosciences announces collaboration with Nasdaq-listed biopharma
CANSF News
By Proactive Investors
October 3, 2023
Willow Biosciences and Suanfarma partner to develop large volume anti-infective API through precision fermentation
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) told investors it has partnered with Spanish life science company Suanfarma to bring sustainably source more_horizontal
By Proactive Investors
September 12, 2023
Willow Biosciences announces $1.2M debt offering
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) announced a non-brokered private placement offering of convertible debenture units, with the goal of ra more_horizontal
By Proactive Investors
September 6, 2023
Willow Biosciences completes R&D to produce ursodeoxycholic acid
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) said it has successfully completed research and development on its program to produce ursodeoxycholic more_horizontal
By Proactive Investors
August 30, 2023
Willow Biosciences files patent application for process to produce much cheaper corticosteroids
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) told investors it has filed a patent application for a process it has developed to produce corticostero more_horizontal
By Proactive Investors
August 24, 2023
Willow Biosciences appoints advisor to review opportunities as part of commercial focus on BioOxi platform
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) announced it has engaged an advisor to assist it with a review of opportunities to enhance value for it more_horizontal
By Proactive Investors
August 21, 2023
Willow Biosciences shares take off on biopharma manufacturing collaboration announcement
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF)' Canadian-listed shares had added more than 23% in the early afternoon on Monday after it announced th more_horizontal
By Proactive Investors
August 21, 2023
Willow Biosciences announces collaboration with Nasdaq-listed biopharma
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) has announced a collaboration with an unnamed Nasdaq-listed biopharma company to develop new sustainab more_horizontal
By Proactive Investors
August 9, 2023
Willow Biosciences secures contracts valued at $1M during 2Q
Willow Biosciences told investors that during the second quarter, it closed three new contracts that are expected to bring in more than $1 million in more_horizontal